|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-5-9
|
|
pubmed:abstractText |
Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:AlteriniRenatoR,
pubmed-author:BettacchiAlbertaA,
pubmed-author:BrandozziGiulianoG,
pubmed-author:FilosaGiorgioG,
pubmed-author:GiacchettiAlfredoA,
pubmed-author:GoteriGaiaG,
pubmed-author:LeoniPietroP,
pubmed-author:MozzicafreddoGiorgioG,
pubmed-author:MulattieriSimonettaS,
pubmed-author:NovelliNicolinoN,
pubmed-author:OffidaniMassimoM,
pubmed-author:PimpinelliNicolaN,
pubmed-author:PuliniStefanoS,
pubmed-author:RicottiGiuseppeG,
pubmed-author:RupoliSerenaS,
pubmed-author:ScortechiniAnna RitaAR,
pubmed-author:SimonacciMarcoM,
pubmed-author:StronatiAndreaA,
pubmed-author:TassettiAngelaA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
686-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17488695-Adult,
pubmed-meshheading:17488695-Aged,
pubmed-meshheading:17488695-Aged, 80 and over,
pubmed-meshheading:17488695-Antineoplastic Agents,
pubmed-meshheading:17488695-Combined Modality Therapy,
pubmed-meshheading:17488695-Disease-Free Survival,
pubmed-meshheading:17488695-Doxorubicin,
pubmed-meshheading:17488695-Female,
pubmed-meshheading:17488695-Follow-Up Studies,
pubmed-meshheading:17488695-Humans,
pubmed-meshheading:17488695-Kaplan-Meier Estimate,
pubmed-meshheading:17488695-Liposomes,
pubmed-meshheading:17488695-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:17488695-Male,
pubmed-meshheading:17488695-Middle Aged,
pubmed-meshheading:17488695-Mycosis Fungoides,
pubmed-meshheading:17488695-Polyethylene Glycols,
pubmed-meshheading:17488695-Prospective Studies,
pubmed-meshheading:17488695-Remission Induction,
pubmed-meshheading:17488695-Salvage Therapy,
pubmed-meshheading:17488695-Sezary Syndrome,
pubmed-meshheading:17488695-Survival Analysis,
pubmed-meshheading:17488695-Survival Rate,
pubmed-meshheading:17488695-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
|
|
pubmed:affiliation |
Clinic of Hematology, Polytechnic University of the Marche, Medical School, Ospedali Riuniti Umberto I, G.M. Lancisi-G. Salesi, Ancona, Italy. stpulini@bigfoot.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
